6 most recent filings and news items mentioning TNXP. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/TNXP/news?limit=20"
Pull TNXP filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayTonix Pharmaceuticals announced positive feedback for the design of an adaptive Phase 2 Lyme disease study of TNX-4800, with plans to begin the trial in early 2027. The long-acting monoclonal antibody offers a potential preventative alternative to vaccines that requires fewer dos
View filing at SEC.gov →Tonix Pharmaceuticals secured a new managed Medicare agreement covering approximately 9 million lives for TONMYA. This expansion significantly broadens total patient access ahead of the January 2027 effective date, enhancing commercial reach.
View filing at SEC.gov →Tonix enrolled the first patient in its Phase 2 HORIZON trial testing TNX-102 SL for major depressive disorder. This potential expansion into MDD builds upon the drug's previous success in fibromyalgia and could open a new market if results are positive.
View filing at SEC.gov →This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
View filing at SEC.gov →Tonix Pharmaceuticals announced a second commercial payer agreement effective June 1, 2026, adding approximately 17 million U.S. lives in coverage for its fibromyalgia drug TONMYA, bringing total commercial coverage to ~52 million lives (29% of U.S. commercial market). The milest
View filing at SEC.gov →Tonix announced publication of Phase 1 clinical data for TNX-1500 in the Journal of Clinical Immunology, showing the drug was well-tolerated with favorable safety profile. A Phase 2 investigator-initiated kidney transplant study at Massachusetts General Hospital is expected to be
View filing at SEC.gov →